Review



nrf2 activator rta 408  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress nrf2 activator rta 408
    Nrf2 Activator Rta 408, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 32 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nrf2 activator rta 408/product/MedChemExpress
    Average 94 stars, based on 32 article reviews
    nrf2 activator rta 408 - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    nrf2 activator rta 408  (MedChemExpress)
    94
    MedChemExpress nrf2 activator rta 408
    Nrf2 Activator Rta 408, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nrf2 activator rta 408/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    nrf2 activator rta 408 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    nrf2 activator rta 408  (Reata Pharmaceuticals)
    90
    Reata Pharmaceuticals nrf2 activator rta 408
    <t>Nrf2-inducers</t> up-regulate the Nrf2 expression in frataxin silenced neurons (shFxn). ( A ) qRT-PCR of mRNA Nrf2 levels in shFxn and Mock after 5 µM (24 h) sulforaphane (SFN) and 30 µM (24 h) dimethyl fumarate (DMF) treatments. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used for normalization and relative quantification of gene expression was performed according to the 2 −ΔΔ C t method; ( B ) Representative Western blot of DMF- and SFN-treated shFxn neurons; ( C ) Densitometry of Nrf2 protein amounts analyzed by Western Blot. Values represent the mean ± SD of three independent experiments (** p < 0.01 and *** p < 0.001, with respect to Mock; # p < 0.05 and ### p < 0.001, with respect to untreated shFxn).
    Nrf2 Activator Rta 408, supplied by Reata Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nrf2 activator rta 408/product/Reata Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    nrf2 activator rta 408 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Nrf2-inducers up-regulate the Nrf2 expression in frataxin silenced neurons (shFxn). ( A ) qRT-PCR of mRNA Nrf2 levels in shFxn and Mock after 5 µM (24 h) sulforaphane (SFN) and 30 µM (24 h) dimethyl fumarate (DMF) treatments. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used for normalization and relative quantification of gene expression was performed according to the 2 −ΔΔ C t method; ( B ) Representative Western blot of DMF- and SFN-treated shFxn neurons; ( C ) Densitometry of Nrf2 protein amounts analyzed by Western Blot. Values represent the mean ± SD of three independent experiments (** p < 0.01 and *** p < 0.001, with respect to Mock; # p < 0.05 and ### p < 0.001, with respect to untreated shFxn).

    Journal: International Journal of Molecular Sciences

    Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

    doi: 10.3390/ijms18102173

    Figure Lengend Snippet: Nrf2-inducers up-regulate the Nrf2 expression in frataxin silenced neurons (shFxn). ( A ) qRT-PCR of mRNA Nrf2 levels in shFxn and Mock after 5 µM (24 h) sulforaphane (SFN) and 30 µM (24 h) dimethyl fumarate (DMF) treatments. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used for normalization and relative quantification of gene expression was performed according to the 2 −ΔΔ C t method; ( B ) Representative Western blot of DMF- and SFN-treated shFxn neurons; ( C ) Densitometry of Nrf2 protein amounts analyzed by Western Blot. Values represent the mean ± SD of three independent experiments (** p < 0.01 and *** p < 0.001, with respect to Mock; # p < 0.05 and ### p < 0.001, with respect to untreated shFxn).

    Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

    Techniques: Expressing, Quantitative RT-PCR, Quantitative Proteomics, Gene Expression, Western Blot

    Nrf2 inducers activate the phase II response in shFxn. ( A ) Representative Western blot of downstream Nrf2 target proteins. An amount of 40 µg Mock, shFxn 5 µM (24 h) SFN and 30 µM (24 h) DMF treatments were applied onto 4–12% Bis–Tris SDS-polyacrylamide gel electrophoresis and probed with anti-NQO-1 (1:1000), MnSOD (1:5000) and Cu/ZnSOD (1:5000) antibodies; ( B ) Densitometry of blots, normalized to GAPDH. Values represent the mean ± SD of three independent experiments (* p < 0.05, with respect to Mock; # p < 0.05, with respect to untreated shFxn).

    Journal: International Journal of Molecular Sciences

    Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

    doi: 10.3390/ijms18102173

    Figure Lengend Snippet: Nrf2 inducers activate the phase II response in shFxn. ( A ) Representative Western blot of downstream Nrf2 target proteins. An amount of 40 µg Mock, shFxn 5 µM (24 h) SFN and 30 µM (24 h) DMF treatments were applied onto 4–12% Bis–Tris SDS-polyacrylamide gel electrophoresis and probed with anti-NQO-1 (1:1000), MnSOD (1:5000) and Cu/ZnSOD (1:5000) antibodies; ( B ) Densitometry of blots, normalized to GAPDH. Values represent the mean ± SD of three independent experiments (* p < 0.05, with respect to Mock; # p < 0.05, with respect to untreated shFxn).

    Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

    Techniques: Western Blot, Polyacrylamide Gel Electrophoresis

    HPLC analysis of GSSG ( A ) and GSH ( B ) in shFxn after treatments with 5 µM (24 h) SFN and 30 µM (24 h) DMF. Nrf2 inducers cause repletion of the oxidized (GSSG)/reduced (GSH) glutathione ratio ( C ). * p < 0.05, *** p < 0.001, with respect to Mock.

    Journal: International Journal of Molecular Sciences

    Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

    doi: 10.3390/ijms18102173

    Figure Lengend Snippet: HPLC analysis of GSSG ( A ) and GSH ( B ) in shFxn after treatments with 5 µM (24 h) SFN and 30 µM (24 h) DMF. Nrf2 inducers cause repletion of the oxidized (GSSG)/reduced (GSH) glutathione ratio ( C ). * p < 0.05, *** p < 0.001, with respect to Mock.

    Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

    Techniques:

    Nrf2-inducers trigger axonal re-growth in the shFxn. ( A ) Bright field photographs of untreated shFxn, 5 µM (24 h) SFN and 30 µM (24 h) DMF treated cells. A re-organization of the neurites network is evident; ( B ) The number of neurites has been measured by ImageJ software and normalized for number of cells (*** p <0.001; bar = 100 μm).

    Journal: International Journal of Molecular Sciences

    Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

    doi: 10.3390/ijms18102173

    Figure Lengend Snippet: Nrf2-inducers trigger axonal re-growth in the shFxn. ( A ) Bright field photographs of untreated shFxn, 5 µM (24 h) SFN and 30 µM (24 h) DMF treated cells. A re-organization of the neurites network is evident; ( B ) The number of neurites has been measured by ImageJ software and normalized for number of cells (*** p <0.001; bar = 100 μm).

    Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

    Techniques: Software

    Expression of NRF2 and its down-stream genes in fibroblasts of patients with FA. Fibroblasts of three patients expressing a 35% residual amount of frataxin and 65% of NRF2 ( A ), with respect to healthy subjects, were treated with 10 µM SFN (24 h), and mRNA levels of NRF2-downstream-genes were determined ( B ). * p < 0.05 and ** p < 0.01, with respect to control fibroblasts; # p < 0.05 and ## p < 0.01, with respect to untreated FA fibroblasts.

    Journal: International Journal of Molecular Sciences

    Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

    doi: 10.3390/ijms18102173

    Figure Lengend Snippet: Expression of NRF2 and its down-stream genes in fibroblasts of patients with FA. Fibroblasts of three patients expressing a 35% residual amount of frataxin and 65% of NRF2 ( A ), with respect to healthy subjects, were treated with 10 µM SFN (24 h), and mRNA levels of NRF2-downstream-genes were determined ( B ). * p < 0.05 and ** p < 0.01, with respect to control fibroblasts; # p < 0.05 and ## p < 0.01, with respect to untreated FA fibroblasts.

    Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

    Techniques: Expressing, Control

    Frataxin and NRF2 mRNA levels in blood of patients with FA. qRT-PCR performed on PBMCs isolated from blood of FA patients ( n = 4) evidenced 35% and 59% residual amounts of Fxn and NRF2 expression, respectively, compared with healthy subjects ( n = 5) (* p < 0.05,** p < 0.01, respect to healthy subjects).

    Journal: International Journal of Molecular Sciences

    Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

    doi: 10.3390/ijms18102173

    Figure Lengend Snippet: Frataxin and NRF2 mRNA levels in blood of patients with FA. qRT-PCR performed on PBMCs isolated from blood of FA patients ( n = 4) evidenced 35% and 59% residual amounts of Fxn and NRF2 expression, respectively, compared with healthy subjects ( n = 5) (* p < 0.05,** p < 0.01, respect to healthy subjects).

    Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

    Techniques: Quantitative RT-PCR, Isolation, Expressing

    Primers used for qRT-PCR.

    Journal: International Journal of Molecular Sciences

    Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

    doi: 10.3390/ijms18102173

    Figure Lengend Snippet: Primers used for qRT-PCR.

    Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

    Techniques: Sequencing